Compare · CBLI vs CRL
CBLI vs CRL
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $8.38B, about 157.8x CBLI ($53.1M).
- CRL has hit the wire 6 times in the past 4 weeks while CBLI has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- Charles River Laboratories International Inc.
- Price
- $3.20-9.22%
- $169.74+1.23%
- Market cap
- $53.1M
- $8.38B
- 1M return
- -
- +2.33%
- 1Y return
- -
- +47.46%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- 2000
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest CRL
- Charles River Highlights Effectiveness of VCGs in Toxicology
- Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
- RBC Capital Mkts initiated coverage on Charles River with a new price target
- Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
- SEC Form 3 filed by new insider Coleman Glenn
- NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
- SEC Form DEF 14A filed by Charles River Laboratories International Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.
- Corporate Executive VP & COO Girshick Birgit gifted 328 shares (SEC Form 4)
- Chairman, President and CEO Foster James C was granted 16,796 shares, increasing direct ownership by 6% to 279,693 units (SEC Form 4)